Needham Maintains Buy on Revolution Medicines, Raises Price Target to $235

Benzinga Newsdesk www.benzinga.com Positive 80.8%

Neg 0% Neu 0% Pos 80.8%

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $183 to $235.